Hepatic resection for colorectal liver metastases: prospective study

Hong Kong Med J. 2002 Oct;8(5):329-33.

Abstract

Objective: To assess the operative and long-term survival outcomes of hepatic resection for colorectal liver metastases during an 11-year period in a tertiary referral centre in Hong Kong.

Design: Prospective study.

Setting: University teaching hospital, Hong Kong.

Subjects and methods: Between January 1989 and December 1999, 72 patients underwent hepatic resection for colorectal liver metastases. Clinical, pathological, and outcome data were prospectively collected and analysed. Factors affecting long-term survival were also evaluated.

Results: Twenty-five (34.7%) patients were found to have synchronous hepatic metastasis at the time of colorectal resection. Fifty-two (72.2%) patients underwent major hepatic resection. The operative morbidity and hospital mortality rates were 19% and 4%, respectively. The 5-year survival rate after hepatectomy was 31.9%. The median disease-free survival and median overall cumulative survival were 18.5 months and 30.8 months, respectively. On multivariate analysis, a high preoperative serum carcinoembryonic antigen level (>200 ng/mL) and tumour involvement of the resection margin at histology were the two independent risk factors that adversely affected survival outcome.

Conclusion: Hepatic resection for colorectal liver metastases can be performed safely, with minimal operative mortality and acceptable morbidity, and results in satisfactory survival. High preoperative serum carcinoembryonic antigen level and histological involvement of resection margin by cancer adversely affect the survival outcome.

MeSH terms

  • Adult
  • Aged
  • Carcinoembryonic Antigen / blood
  • Carcinoma / secondary*
  • Carcinoma / surgery
  • Colorectal Neoplasms / pathology*
  • Disease-Free Survival
  • Female
  • Hepatectomy*
  • Hong Kong
  • Humans
  • Liver Neoplasms / blood
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / surgery
  • Male
  • Middle Aged
  • Prospective Studies
  • Survival Rate
  • Treatment Outcome

Substances

  • Carcinoembryonic Antigen